Gayatri Made, Jyothi Swapna Raparthi, Vinod Kumar Mugada, Srinivasa Rao Yarguntla
Gayatri Made1*, Jyothi Swapna Raparthi1, Vinod Kumar Mugada1, Srinivasa Rao Yarguntla2
1Department of Pharmacy Practice, Vignan Institute of Pharmaceutical Technology, Duvvada, AP, India.
2Department of Pharmaceutics, Vignan Institute of Pharmaceutical Technology, Duvvada, AP, India.
Volume - 15,
Issue - 4,
Year - 2023
Kallmann syndrome (KS) is an uncommon disorder that was first defined in 1856 and designed by Kallmann in 1944. It is also referred to as olfactogenital dysplasia and is characterized by hypogonadism and the agenesis of the olfactory bulb. The prevalence of KS is not well understood, with the incidence in males ranging from 1 in 8000 to 1 in 10,000 and being less common in females. Kallmann syndrome exhibits genetic heterogeneity, with the inheritance of the trait occurring in an autosomal recessive, autosomal dominant, or X-linked manner. Over 24 genes have been determined to be responsible for Kallmann syndrome, which is thought to be caused by mutations that inhibit the formation of cell markers necessary for the migration of olfactory and GnRH (gonadotropin-releasing hormone) neurons to the forebrain during foetal development. Kallmann syndrome is characterised by hypogonadotropic hypogonadism and hyposmia or anosmia. Other less common symptoms include osteoporosis, cleft lip and palate, cryptorchidism, unilateral renal agenesis, and cardiovascular problems. Magnetic resonance imaging (MRI) can help detect anomalies in the olfactory system and other forebrain regions, as well as pituitary disorders. The treatment for Kallmann syndrome typically involves hormone replacement therapy (HRT) with both testosterone and gonadotropin-releasing hormone (GnRH) analogues to stimulate puberty and promote secondary sexual characteristics.
Cite this article:
Gayatri Made, Jyothi Swapna Raparthi, Vinod Kumar Mugada, Srinivasa Rao Yarguntla. Facing the Challenge: Hormonal hurdles, Olfaction Obstacles in Kallmann Syndrome. Research Journal of Pharmacology and Pharmacodynamics.2023;15(4):212-6. doi: 10.52711/2321-5836.2023.00037
Gayatri Made, Jyothi Swapna Raparthi, Vinod Kumar Mugada, Srinivasa Rao Yarguntla. Facing the Challenge: Hormonal hurdles, Olfaction Obstacles in Kallmann Syndrome. Research Journal of Pharmacology and Pharmacodynamics.2023;15(4):212-6. doi: 10.52711/2321-5836.2023.00037 Available on: https://rjppd.org/AbstractView.aspx?PID=2023-15-4-11
1. Noorian S, Savad S, Khavandegar A, Jamee M. A Family with Novel X-linked recessive Homozygous mutation in ANOS-1 gene (c.628_629 del, p.1210fs*) in Kallmann syndrome associated unilateral ptosis; A case report and review of the literature. AACE Clin Case Rep. 2021 Feb;7(1):67-72
2. Arkoncel MLCR, Arkoncel FRP, Lantion-Ang FL. A case of Kallmann syndrome. Case Rep. 2011 Mar 25;2011:bcr0120113727.
3. Stamou MI, Georgopoulos NA. Kallmann syndrome: phenotype and genotype of hypogonadotropic hypogonadism. Metabolism. 2018 Sep;86:124-134.
4. Sonne J, Lopez-Ojeda W. Kallmann Syndrome [Internet]. PubMed. Treasure Island (FL): StatPearls Publishing; 2020.
5. Tsai PS, Gill JC. Mechanisms of disease: insights into X-linked and autosomal-dominant Kallmann syndrome. Nat Clin Pract Endocrinol Metab. 2006 Mar;2(3):160-171.
6. Boehm U, Bouloux PM, Dattani MT, de Roux N, Dodé C, Dunkel L, et al. European Consensus Statement on congenital hypogonadotropic hypogonadism—pathogenesis, diagnosis and treatment. Nat Rev Endocrinol. 2015 Sep;11(9):547-564.
7. Eppy Buchori Aristiady, Alberta D. A rare case of a 34-year-old patient diagnosed late with Kallmann syndrome: case report. J Med Case Rep. 2022 Jan 1;16(1):4.
8. Bhagavath B, Xu N, Ozata M, Rosenfield RL, Bick DP, Sherins RJ, et al. KAL1 mutations are not a common cause of idiopathic hypogonadotrophic hypogonadism in humans. MHR Basic Sci Reprod Med. 2007 Jan 9;13(3):165-170.
9. Corona G, Vignozzi L, Sforza A, Maggi M. Risks and Benefits of Late Onset Hypogonadism Treatment: An Expert Opinion. World J Mens Health. 2013 Aug;31(2):103-125.
10. Franco B, Guioli S, Pragliola A, Incerti B, Bardoni B, Tonlorenzi R, et al. A gene deleted in Kallmann's syndrome shares homology with neural cell adhesion and axonal path-finding molecules. Nature. 1991 Oct 10;353(6344):529-536.
11. Hu Y, Guimond SE, Travers P, Cadman S, Hohenester E, Turnbull JE, et al. Novel Mechanisms of Fibroblast Growth Factor Receptor 1 Regulation by Extracellular Matrix Protein Anosmin-1. J Biol Chem. 2009 Aug 21;284(34):29905-29920.
12. Bülow HE, Berry K, Topper LH, Peles E, Hobert O. Heparan sulfate proteoglycan-dependent induction of axon branching and axon misrouting by the Kallmann syndrome gene kal-1. J Neurosci. 2002 Apr 30;22(9):6346-6351.
13. Miraoui H, Dwyer AA, Sykiotis GP, Plummer L, Chung W, Feng B, et al. Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 Are Identified in Individuals with Congenital Hypogonadotropic Hypogonadism. Am J Hum Genet. 2013 May 2;92(5):725-743.
14. Navarro VM, Tena-Sempere M. Neuroendocrine control by kisspeptins: role in metabolic regulation of fertility. Nat Rev Endocrinol. 2011 Jan;8(1):40-53.
15. Mayer C, Acosta-Martinez M, Dubois SL, Wolfe A, Radovick S, Boehm U, et al. Timing and completion of puberty in female mice depend on estrogen receptor α-signaling in kisspeptin neurons. Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):22693-22698.
16. Pinilla L, Aguilar E, Dieguez C, Millar RP, Tena-Sempere M. Kisspeptins and Reproduction: Physiological Roles and Regulatory Mechanisms. Physiol Rev. 2012 Jul;92(3):1235-1316.
17. Quennell JH, Mulligan AC, Tups A, Liu X, Phipps SJ, Kemp CJ, et al. Leptin Indirectly Regulates Gonadotropin-Releasing Hormone Neuronal Function. Endocrinology. 2009 Jun;150(6):2805–12.
18. Dodé C, Hardelin JP. Kallmann syndrome. Eur J Hum Genet. 2008 Feb;17(2):139-146.
19. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969 Jun;44(235):291-303.
20. Quinton R, Duke V, De A, Platts AD, Valentine A, Kendall B, et al. The neuroradiology of Kallmann's syndrome: a genotypic and phenotypic analysis. J Clin Endocrinol Metab. 1996 Aug;81(8):3010-3017.
21. Sykiotis GP, Hoang XH, Avbelj M, Hayes FJ, Thambundit S, Dwyer AA, et al. Congenital idiopathic hypogonadotropic hypogonadism: evidence of defects in the hypothalamus, pituitary, and testes. J Clin Endocrinol Metab. 2010 Jun;95(6):3019-3027.
22. Au MG, Crowley WF, Buck C. Genetic counseling for isolated GnRH deficiency. J Pediatr Endocrinol Metab. 2011 Oct 1;24(1-2):102-109.
23. Sarfati J, Bouvattier C, Bry-Gauillard H, Cartes A, Bouligand J, Young J. Kallmann syndrome with FGFR1 and KAL1 mutations detected during fetal life. Orphanet Journal of Rare Diseases. 2015;10(1):71.
24. Xu N, Qin Y, Reindollar RH, Tho SP, McDonough PG, Layman LC. A mutation in the fibroblast growth factor receptor 1 gene causes fully penetrant normosmic isolated hypogonadotropic hypogonadism. Mol Hum Reprod. 2007 Mar;13(3):165-170.
25. Balasubramanian R, Crowley WF. Isolated Gonadotropin-Releasing Hormone (GnRH) Deficiency [Internet]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Stephens K, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993.
26. Novo A, Guerra I, Rocha F, Gama-de-Sousa S, Borges T, Cerqueira R, et al. Kallmann syndrome in a female adolescent: a new mutation in the FGFR1 gene. BMJ Case Rep. 2012 Jun 29;2012:bcr1220115380.
27. Messinis IE. Ovulation induction: a mini review. Hum Reprod. 2005 Oct;20(10):2688-2697.
28. Zhang P, Fu J. X-linked recessive Kallmann syndrome: A case report. Exp Ther Med. 2022 Nov;24(5):8990-8997.
29. Sakat BT, Sakhare RB, Suryvanshi UC, Kore PS, S.V. Mohite, Magdum CS. Osteoporosis: The Brittle Bone. 2018 Jan 1;8(1):39–9.
30. Rasha Saad Aldoury, Ali Yousif Nori, Sarah Ahmed Khalid. Comparative Study between some Parameters in Ultrasonography and Renal Scintigraphy in the Evaluation of Hydronephrosis among Iraqi Paediatric Patients. 2023 Feb 28;733–9.
31. Shruti Shrey, Amol Singam. A Comparative Study of Atracurium and Cisatracurium in paediatric cleft Lip and Cleft palate Surgeries. 2020 Jan 1;13(2):867–7.